Introduction {#sec1}
============

Coronary heart disease is the most common cause of morbidity and mortality worldwide, and its prevalence is steadily increasing, accounting for up to 12.8% of overall mortality \[[@cit0001]\]. During the last two decades, the advances of reperfusion therapies, such as primary coronary angioplasty (PCA), have significantly reduced the acute myocardial infarction (AMI)-related mortality burden and improved the clinical outcomes of patients \[[@cit0002]\]. Aside from the ischemic necrotic area, restoring oxygen flow paradoxically causes further cell death through rapid and massive myocardial necrosis along with less intense yet more prolonged apoptosis and autophagy processes. These events lead to the configuration of a phenomenon known as myocardial reperfusion injury (MRI), which likely accounts for up to 50% of the final infarct size \[[@cit0003]\] and also leads to different complications, such as reperfusion arrhythmias and myocardial stunning \[[@cit0004]\]. A growing body of evidence suggests that this damage could be the result of oxidative stress generated in the cardiac tissue and triggered by both oxygen reactive species (ROS) and nitrogen reactive species (RNS) \[[@cit0005]\]. During ischemia, intracellular ROS production increases due to uncoupling of the mitochondrial respiratory chain, consuming residual oxygen, and a decrease in antioxidant defenses \[[@cit0005]\], leading to oxidative damage, inflammatory responses and cellular death by apoptotic, necrotic and autophagic pathways \[[@cit0006]\]. During reperfusion, the sudden increase in oxygen supply to the endothelium, cardiomyocytes and other cell types amplifies the basal rate of ROS production several times, mainly superoxide anion (O~2~^--^), and reaches a peak during the first few minutes \[[@cit0007]\]. The main sources of ROS include uncoupled endothelial nitric oxide synthase (NOS), mitochondria, fatty acid oxidation, xanthine oxidase activity and mainly NADPH oxidase activity \[[@cit0005], [@cit0008]\]. This activates pro-inflammatory pathways such as nuclear factor-κB, triggering inflammation and apoptosis signaling \[[@cit0009]\]. In addition, inducible NOS activity enhances nitric oxide (NO) production, which rapidly reacts with O~2~^--^, generating the highly toxic RNS peroxynitrite, which enhances free radical damage \[[@cit0010]\].

Taking into account that ROS produces rapid and irreversible damage to myocardial tissue and other organs, it is plausible that antioxidants may counteract this damage \[[@cit0011]--[@cit0015]\]. Numerous attempts using pharmacological strategies have targeted oxidative stress to prevent this phenomenon, but none of them have succeeded, probably due to a lack of consideration of the basic pharmacokinetic and pharmacodynamic aspects of antioxidants \[[@cit0005]\]. Ascorbate has been one of the most widely used antioxidants for this purpose due to its ability to directly reduce ROS \[[@cit0011]\]. In addition to its ROS scavenger actions, it exerts a complex modulation of numerous enzymes involved in ROS production, endothelial dysfunction, platelet aggregation and smooth muscle cell tone \[[@cit0016]\]. Ascorbate increases NO synthesis, reduces ROS formation and contributes to the regulation of vascular tone \[[@cit0017], [@cit0018]\].

Taking into account the above considerations, a rational therapy for preventing MRI could involve the use of ascorbate prior to reperfusion to enhance the antioxidant potential of myocardial tissue \[[@cit0005]\]. Two key aspects have to be considered with regard to this issue. First, ascorbate should be administered before the onset of reperfusion. Second, ascorbate has to reach high enough levels to counteract the superoxide and NO reactions, occurring at a rate that is 10^5^-fold greater than that at which superoxide reacts with ascorbic acid \[[@cit0019]\]. Accordingly, 10 mmol/l ascorbate is needed to effectively achieve its cardioprotective properties. This concentration is only reachable by giving intravenous ascorbate, which has been proven to be completely safe \[[@cit0020]\].

The aim of this study was to test the hypothesis that an ascorbate-based supplementation protocol can ameliorate MRI associated with reperfusion following PCA.

Material and methods {#sec2}
====================

The protocol consisted of a randomized, multicenter, double-blind, placebo-controlled trial (ISRCTN registry: 56034553) conducted in 99 either-sex patients who had a diagnosis of ST-segment elevation acute myocardial infarction (STEMI) and an indication for primary PCA (angina and an electrocardiogram with an STEMI that concerned more than two contiguous leads \> 2 mm). The presentation should have occurred within 12 h of the onset of symptoms. Only patients older than 18 years who experienced their first myocardial infarction were enrolled. The patient enrolment took place from February 2013 to November 2015. The cardiovascular units involved in the study included the University of Chile Clinical Hospital, San Juan de Dios Hospital, and San Borja Arriarán Clinical Hospital. The exclusion criteria included a history of renal or hepatic insufficiency, heart failure (NYHA III or IV), cardiogenic shock, post-primary PCA TIMI grade flow \< 3, any serious medical comorbidity that indicated a life expectancy \< 6 months, pregnancy, history of renal stones, and glucose 6-phosphate dehydrogenase deficiency. Other causes of exclusion during follow-up are shown in [Figure 1](#f0001){ref-type="fig"}.
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CMR -- cardiac magnetic resonance.](AMS-13-27497-g001){#f0001}

Study population {#sec2.1}
----------------

The participants were randomized at the time of enrolment to placebo (*n* = 53) or ascorbate-treatment groups (*n* = 46). The randomization sequence was centrally generated, stored, and assigned by using online randomization software in random permuted blocks, each consisting of a box containing six treatment kits allocated in a placebo-to-vitamin treatment in a 1 : 1 ratio for each participating center. The treatment was initiated immediately after the randomization. For subjects allocated to the ascorbate-treatment group, the protocol began by administering an intravenous infusion of sodium ascorbate (320 mmol/l) at a flow rate of 10 ml/min during the initial hour and at 3 ml/min during the following 2 h.

After the initial evaluation, the subjects in both groups were admitted to the catheterization laboratory in accordance with the standard protocol for AMI. An angiography was performed to identify the infarct-related artery, percentage of stenosis, and initial TIMI flow. Primary PCA was performed according to the current guidelines of each cardiovascular center. Catheterization was performed through the radial or femoral artery according to the clinician's decision. Then, the catheter was inserted into the artery and threaded to the coronary vessel. Once the occluded area was identified, balloon dilatation was carried out only in the culprit artery. The stent device implantation was decided according to need and the judgment of the physician in charge of the procedure. After the primary PCA, oral doses of ascorbate (500 mg/12 h) and α-tocopherol (400 IU/day) were orally administered to the patients for 84 continuous days. For the subjects allocated to the placebo group, the oral dose of ascorbate was replaced with vegetable oil capsules (Procaps). The intravenous infusion of ascorbate was replaced with an equal volume of a sodium chloride solution having the same osmolality as the ascorbate infusion that was administered to patients in the ascorbate group. The pharmaceutical forms of ascorbate were indistinguishable from their respective placebo.

Cardiac magnetic resonance assessment {#sec2.2}
-------------------------------------

In 67 patients, cardiac magnetic resonance (CMR) assessments were performed 7--15 days after primary PCA (first CMR). In a subgroup of 40 patients, a second CMR was performed 2--3 months following primary PCA (second CMR). The magnetic resonance scanner specifications were as follows: Model: Siemens Sonata 1.5 tesla. Coil: 4-channel array coil. The imaging protocol included a cine balanced SSFP sequence and an inversion recovery PSIR sequence 10 min after the administration of 2 mmol/kg of intravenous gadolinium. Each sequence was performed in 7-mm slices in the short axis plane from the base to the apex and in the 2- and 4-chamber planes. Images were analyzed with the Argus software (Siemens, Germany) for the volumes and ejection fraction of the left ventricle, as well as with the segment software v1.9 (<http://segment.heiberg.se>) for quantification of the infarct size \[[@cit0021]\]. Both the determination and data obtained by these procedures were evaluated by 2 independent individuals who were blinded to the clinical data of the patients.

Laboratory tests {#sec2.3}
----------------

Immediately before the coronary artery occlusion was confirmed, a basal blood sample was drawn from the antecubital vein (M1). Three more blood samples were obtained at different times: immediately after reperfusion onset (M2), 6--8 h after balloon deflation (M3) and on hospital discharge (M4). Plasma samples were separated by blood centrifugation (3000 g for 10 min). The red blood cell sediment was washed twice with saline and then subjected to hypotonic hemolysis with distilled water. The plasma and red blood cell lysate samples were stored at --80°C.

The plasma ascorbate concentration was determined by the fluorometric method \[[@cit0022]\]. The intracellular redox status in erythrocytes was assessed by measuring reduced glutathione (GSH) by fluorometry \[[@cit0023]\]. The antioxidant capacity of the plasma was assessed by the ferric reducing ability of plasma (FRAP) assay \[[@cit0024]\]. The plasma creatine kinase-MB (CK-MB) and total creatine kinase concentrations were measured using standard methods.

Outcomes {#sec2.4}
--------

The primary outcome was defined as an infarct size assessment by CMR at 7--15 days. The secondary outcomes were an infarct size assessment by CMR at 2--3 months, left ventricular ejection fraction (LVEF) and indexed end-systolic volume (IESV) in both CMRs, antioxidant intracellular (GSH) and extracellular (FRAP) potential and plasma concentrations of creatine kinase-MB (CK-MB).

Statistical analysis {#sec2.5}
--------------------

The Shapiro-Wilk test and distribution plots were used to test the normality of the distribution. The results were expressed as the mean ± the standard deviation for the parametric variables and the median plus the interquartile range for the non- parametric variables. Significant differences for the normally distributed variables were compared by Student's *t*-test, whereas non-normally distributed variables were compared using the Mann-Whitney *U* test. Comparisons of the categorical variables among the different groups of patients were performed by means of the χ^2^ test. The difference between the groups was considered significant with a *p*-value \< 0.05. All statistical analyses were performed using Stata version 10.1 (Stata Corporation) and Graph Pad Prism 5.0.

Ethics {#sec2.6}
------

All procedures performed in the study were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval of the study was obtained from the local Institutional Ethics Committees. Informed written consent was obtained from all participants before initiating any participation in the trial.

Results {#sec3}
=======

The study population consisted of 99 patients with comparable baseline characteristics. Thirty-two patients were excluded. Sixty-seven patients underwent a CMR assessment on days 7--15, and 40 patients completed the follow-up with a second CMR after 2--3 months ([Figure 1](#f0001){ref-type="fig"}). Four patients died during follow up, 3 from cardiogenic shock and 1 from nosocomial pneumonia. There were no adverse events that could be attributed to the antioxidant supplementation treatment ([Table I](#t0001){ref-type="table"}).

###### 

Baseline characteristics of enrolled patients

  Variable                                         Placebo         Ascorbate       Total           *P*-value
  ------------------------------------------------ --------------- --------------- --------------- -----------
  *N*                                              53              46              99              
  Age \[years\]                                    56.16 ±8.51     59.2 ±11.98     57.47 ±10.2     0.7801
  Systolic BP at admission \[mm Hg\]               152.56 ±15.42   147.89 ±43.01   150.17 ±28.08   0.4530
  Diastolic BP at admission \[mm Hg\]              87.10 ±6.57     90.98 ±67.21    89.25 ±15.08    0.4580
  Heart rate \[beats/min\]                         78.80 ±4.32     80.11 ±24.01    79.67 ±18.28    0.6742
  BMI \[kg/m^2^\]                                  29.2 ±4.52      26.62 ±4.71     28.00 ±4.70     0.5512
  Onset of symptoms -- balloon angioplasty \[h\]   5.27 ±2.78      5.07 ±2.50      5.20 ±2.63      0.8102
  Mortality 3 months, *n* (%)                      2 (3.77)        2 (4.34)        4 (4.04)        0.7123
  Recurrence of AMI -- 3 months, *n* (%)           0 (0)           0 (0)           0 (0)           --
  Comorbidities, *n* (%):                                                                          
   Hypertension                                    14 (26.41)      13 (28.26)      27 (27.27)      0.9050
   Diabetes mellitus                               7 (13.21)       2 (4.34)        9 (9.09)        0.1231
   Smoking                                         16 (30.19)      15 (32.61)      31 (31.31)      0.2410
   Dyslipidemia                                    10 (18.87)      4 (8.69)        14 (14.14)      0.1982
  Previous drug treatment, *n* (%):                                                                
   ACE inhibitor and/or ARBs                       7 (13.21)       6 (13.04)       13 (13.13)      0.2904
   Aspirin                                         4 (7.54)        4 (8.69)        8 (8.08)        0.5509
   β-Blockers                                      5 (9.43)        4 (8.69)        9 (9.09)        0.4464
   Statins                                         3 (5.66)        2 (4.34)        5 (5.05)        0.6098
   Diuretics                                       8 (15.09)       10 (21.74)      18 (18.18)      0.3659
   Calcium channel blockers                        1 (1.88)        1 (2.17)        4 (4.04)        0.5233
   Nitrates                                        0 (0.00)        0 (0.00)        0 (0.00)        --
   Fibrates                                        1 (1.88)        0 (0.00)        1 (1.01)        0.2420
   Aldosterone receptor antagonist                 1 (1.88)        0 (0.00)        1 (1.01)        0.2420
   Antiarrhythmic                                  0 (0.00)        0 (0.00)        0 (0.00)        --
   Anticoagulants                                  0 (0.00)        0 (0.00)        0 (0.00)        --
  Post-follow-up drug treatment:                                                                   
   *N*                                             25              15              40              
   ACE inhibitor and/or ARBs, *n* (%)              25 (100.00)     15 (100.00)     40 (100.00)     --
   Aspirin, *n* (%)                                25 (100.00)     15 (100.00)     40 (100.00)     --
   β-Blockers, *n* (%)                             25 (100.00)     15 (100.00)     40 (100.00)     --
   Statins, *n* (%)                                25 (100.00)     15 (100.00)     40 (100.00)     --
   Diuretics, *n* (%)                              6 (24.00)       3 (20.00)       9 (22.50)       0.4190
   Calcium channel blockers, *n* (%)               2 (8.00)        1 (6.66)        3 (7.50)        0.4503
   Aldosterone receptor antagonist, *n* (%)        1 (4.00)        1 (6.66)        2 (5.00)        0.6129
   Antiarrhythmic, *n* (%)                         0 (0.00)        0 (0.00)        0 (0.00)        --
   Anticoagulants, *n* (%)                         0 (0.00)        0 (0.00)        0 (0.00)        --

An intention-to-treat analysis was considered. Values are expressed as n (%) or mean ± standard deviation. BP -- blood pressure, BMI -- body mass index, AMI -- acute myocardial infarction, ACE -- angiotensin-converting enzyme, ARBs -- angiotensin II receptor blockers, NS -- non-significant.

Clinical characteristics {#sec3.1}
------------------------

The baseline characteristics of the study population are presented in [Table I](#t0001){ref-type="table"}. Angiographic characteristics were also registered ([Table II](#t0002){ref-type="table"}). During a median follow-up of 3 months, the primary outcome of the study was analyzed in 40 (40.4%) participants. Fifty-nine patients were excluded from the study ([Figure 1](#f0001){ref-type="fig"}).

###### 

Angiographic characteristics of enrolled patients

  Variable                       Placebo (*n* = 53)   Ascorbate (*n* = 46)   Total (*n* = 99)   *P*-value
  ------------------------------ -------------------- ---------------------- ------------------ -----------
  Compromised artery, *n* (%):                                                                  
   Anterior descending artery    27 (50.94)           24 (50.00)             51 (51.51)         0.2524
   Right coronary artery         21 (39.62)           12 (26.09)             33 (33.33)         0.2351
   Circumflex artery             5 (9.43)             10 (21.74)             15 (15.15)         0.5812
  Surgical approach, *n* (%):                                                                   
   Radial artery                 51 (96.22)           40 (86.95)             91 (91.91)         0.7910
   Femoral artery                2 (3.77)             6 (14.04)              8 (8.08)           0.7012
  Initial TIMI flow, *n* (%):                                                                   
   0--1                          45 (84.91)           35 (76.09)             80 (80.80)         0.5460
   2--3                          8 (15.09)            11 (23.91)             19 (19.19)         0.8124
  Final TIMI flow, *n* (%):                                                                     
   0--1                          2 (3.77)             4 (8.69)               6 (6.06)           0.2452
   2--3                          51 (96.23)           42 (91.31)             93 (93.93)         0.3949

An intention-to-treat analysis was considered. Values are expressed as n (%). NS -- non-significant.

Cardiac resonance magnetic assessment {#sec3.2}
-------------------------------------

There was no significant difference in infarct size between the groups either in the first or the second CMR ([Table III](#t0003){ref-type="table"}).

###### 

Cardiac resonance assessments

  Outcome             Placebo (*n* = 25)   Ascorbate (*n* = 15)   *P*-value
  ------------------- -------------------- ---------------------- -----------
  Infarct size (%):                                               
   7--15 days         21.5 (17.0--34.2)    17.0 (13.0--36.0)      0.6646
   2--3 months        19.0 (14.0--34.0)    21.0 (14.0--34.0)      0.9642
  LVEF (%):                                                       
   7--15 days         49.1 (41.0--59.4)    47.3 (40.0--56.4)      0.5403
   2--3 months        47.5 (38.0--61.7)    54.6 (39.9--64.8)      0.4155
  IESV \[ml/m^2^\]:                                               
   7--15 days         45.0 (28.2--53.4)    46.9 (25.0--54.5)      0.8461
   2--3 months        47.0 (34.0--56.5)    39.0 (25.0--60.8)      0.3890

Values are expressed as median (interquartile range). LVEF -- left ventricular ejection fraction, IESV -- indexed end systolic volume.

The LVEF assessed by CMR and the IESV also showed no significant difference between groups in the first or second CMR ([Table III](#t0003){ref-type="table"}). Additionally, to analyze the individual changes in the LVEF experienced by the patients in both groups throughout the follow-up, the difference between the LVEF obtained in the two CMRs after the PCA was calculated (Delta LVEF). The changes in the LVEF obtained with this method showed significantly higher values for the ascorbate group than for the placebo group (*p* \< 0.05) ([Figure 2](#f0002){ref-type="fig"}).

![Difference between the LVEF obtained in the two CMRs after the PCA (Delta LVEF) (*n* placebo = 25; *n* ascorbate = 15). Mann-Whitney *U* test was applied. The delta LVEF obtained with this method showed significantly higher values for the ascorbate group than for the placebo group](AMS-13-27497-g002){#f0002}

Oxidative stress-related parameters and cardiac biomarkers {#sec3.3}
----------------------------------------------------------

The mean plasma ascorbate and FRAP levels were significantly higher in M2 and M3 in the ascorbate group compared to the placebo group (*p* \< 0.05). The erythrocyte GSH levels showed no significant differences between the groups at M1 or M4. However, at M2 and M3, the GSH levels for the ascorbate group were half of the respective placebo values (*p* \< 0.05). The levels of the myocardial damage biomarker CK-MB were not significantly different between the groups at baseline or 6--8 h after PCA ([Table IV](#t0004){ref-type="table"}).

###### 

Oxidative stress-related parameters and cardiac biomarkers

  Parameter   Plasma ascorbate \[mmol/l\]   FRAP \[μmol/l\]     GSH \[mmol/l\]   CKMB \[U/l\]                                                                                                                                                        
  ----------- ----------------------------- ------------------- ---------------- --------------------------- ---------------------- ----------- ------------------- ------------------- -------- ------------------------- ------------------------- --------
  *N*         15                            25                                   15                          25                                 15                  25                           15                        25                        
  M1          0.04 (0.02--0.09)             0.02 (0.01--0.05)   0.9674           271.7 (200.2--396.4)        304.1 (213.0--429.6)   0.3043      4.11 (3.61--6.56)   3.59 (3.21--4.54)   0.7714   41.00 (22.40--98.00)      33.00 (24.00--69.00)      0.4092
  M2          9.63 (6.25--11.64)            0.02 (0.01--0.03)   \< 0.0001        8050.0 (50275.0--11418.0)   310.3 (227.7--400.0)   \< 0.0001   3.71 (1.75--4.60)   3.92 (3.26--5.28)   0.0149   --                        --                        
  M3          0.72 (0.23--2.43)             0.02 (0.01--0.04)   \< 0.0001        1080.0 (699.9--2062.0)      287.5 (250.2--391.2)   \< 0.0001   2.59 (1.61--4.15)   4.13 (3.48--5.06)   0.0198   335.50 (134.00--478.30)   387.00 (189.00--725.00)   0.6642
  M4          0.02 (0.01--0.05)             0.03 (0.01--0.05)   0.8023           378.2 (257.9--464.3)        352.2 (220.0--371.8)   0.3568      3.87 (3.55--4.86)   4.02 (3.34--4.43)   0.7512   --                        --                        

Values are expressed as median (interquartile range). M1 -- basal blood sample, M2 -- immediately after reperfusion, M3 -- 6 to 8 h after balloon deflation, M4 -- at hospital discharge, Asc -- ascorbate group, FRAP -- ferric reducing ability of plasma, GSH -- reduced glutathione, CKMB -- creatine kinase MB.

Discussion {#sec4}
==========

This study presents a novel strategy for protecting the heart against reperfusion damage based on the administration of high doses of ascorbate to patients with AMI who are undergoing primary PCA. We previously presented preliminary data, demonstrating for the first time that high plasma ascorbate levels significantly improved microvascular dysfunction \[[@cit0025]\].

This study was based on the paradigm of cardioprotection resulting from the high antioxidant doses that we previously presented \[[@cit0011]\]. Ascorbate patients did not show a significant difference in infarct size, ejection fraction, or the prespecified CMR outcomes, compared to the placebo group. However, we found that ascorbate patients showed an improvement in change of ejection fraction determined with CMR between 7--15 days and 2--3 months. Although this parameter was not a prespecified one, it hints at a possible functional effect of our ascorbate protocol.

We attempted to minimize the deleterious effect of oxidative stress in ischemia--reperfusion injury to achieve a marked enhancement of the blood antioxidant potential at the onset of reperfusion. In fact, the higher plasma FRAP levels in the ascorbate group ([Table IV](#t0004){ref-type="table"}) should involve an increased capacity to mitigate the oxidative damage associated with reperfusion. This favorable condition was maintained for at least 6--8 h following the onset of reperfusion, a phase characterized by the prevalence of a pro-oxidant state. However, high plasma ascorbate levels were accompanied by an unexpected decrease in the intracellular antioxidant capacity, as assessed by a decreased erythrocyte GSH ([Table IV](#t0004){ref-type="table"}). A possible mechanistic explanation for this phenomenon is that GSH consumption is due to the recycling of ascorbate \[[@cit0026]--[@cit0028]\]. The decreased erythrocyte GSH levels could lead to increased vulnerability of cardiac tissue to oxidative damage. Nevertheless, there was no evidence of increased damage because supplemented patients did not have either a higher infarct size or increased cardiac injury serum biomarkers ([Tables III](#t0003){ref-type="table"} and [IV](#t0004){ref-type="table"}, respectively). Instead, patients in the ascorbate group achieved a functional benefit in the ejection fraction ([Figure 2](#f0002){ref-type="fig"}). Therefore, further studies are needed to determine the actual mechanism through which ascorbate influences the redox status in these patients.

The morphological and functional effects of ascorbate in this setting were assessed through CMR imaging, which is widely accepted as the gold standard for measuring infarct size in clinical practice \[[@cit0029]--[@cit0033]\]. In addition, CMR allows accurate and reproducible measurements of the ejection fraction, ventricular volumes and cardiac mass \[[@cit0029]\]. We chose the infarct size because it has been established as an important trial outcome by the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction \[[@cit0034]\]. Furthermore, infarct size is a validated assessment in trials that evaluate the amelioration of reperfusion injury \[[@cit0035]--[@cit0037]\] because its variation reflects the interaction of multiple physiologic and metabolic factors while providing a direct measure of the amount of myocardial cell loss \[[@cit0038]\].

Our results further suggest functional improvement of the ventricle induced by ascorbate. It is noteworthy that in the CMRs performed on days 7--15, the ejection fraction was similar in both groups, and the differences were not evident until 2--3 months following PCA. The mechanism whereby the present intervention ameliorated the persistent ejection fraction impairment remains to be elucidated. An analysis of these results should take into consideration the fact that previous studies performed using oral antioxidants alone following AMI showed no improvement in clinical outcomes \[[@cit0039]\]. Therefore, it may be plausible to assume that the high plasma ascorbate concentration that was achieved early during reperfusion played a key role in triggering this beneficial effect. It is likely that the FRAP elevation due to high plasma ascorbate levels at the onset of reperfusion are able to exert a prophylactic effect against the lethal reperfusion occurring during primary PCA \[[@cit0005]\]. To our knowledge, there are no previous studies using ascorbate doses that are capable of achieving the plasma concentrations reached in this study.

Previous attempts to prevent MRI through antioxidants showed disappointing results \[[@cit0040]\]. These studies included different types of antioxidants, including ascorbate, without clinical benefit \[[@cit0041]--[@cit0045]\]. There are basic pharmacokinetic aspects of ascorbate that may explain why our intervention showed an effective clinical benefit based on the following considerations:

-   Patients in the ascorbate group exhibited ascorbate levels high enough to block the reaction of superoxide with nitric oxide (\> 10 mmol/l) -- levels that could not be reached by oral doses in the previous studies.

-   Ascorbate was administered prior to the onset of reperfusion, when the MRI occurs. It should be taken into account that ROS burst and MRI occur immediately after the coronary blood flow restoration \[[@cit0007]\], and all the strategies aimed at preventing MRI should be applied prior to reperfusion \[[@cit0011]\].

The analysis of these results is subject to inherent limitations. First, at the moment of enrolment, many patients with a clinical diagnosis of AMI (angina and EKG classic characteristics) presented with an initial TIMI flow \> 1, independent of primary PCA. Furthermore, we could not document the exact time of onset of reperfusion. Clinical follow-up and laboratory tests, but not CMR, were performed in these patients. Second, despite using the most validated method to assess infarct size, the main limitation of our study was the absence of a method for determining the start point of myocardial damage (area at risk). This area depends on many factors, including a compromised artery, occluded segment, myocardial collateral irrigation, individual myocardial anatomy characteristics, and frequent variability in the anatomic distribution of the coronary arteries. Third, in a few cases, it was particularly difficult to assess the ischemia time due to the atypical presentations of AMI we well as the different pain threshold of some patients (e.g.: diabetics and older patients). Fourth, contrast enhanced CMR has absolute and relative contraindications, such as claustrophobia, renal failure, arrhythmia and severe dyspnea, which led to a significant drop in the number of patients who could participate in the primary outcome analyses ([Figure 1](#f0001){ref-type="fig"}).

In conclusion, the present study was designed to determine the cardioprotective effect of ascorbate in AMI patients undergoing primary PCA. The results support the view that a high intravenous dose administration prior to reperfusion onset followed by oral doses of ascorbate did not result in amelioration of infarct size or ejection fraction. However, we found that the ascorbate group showed an improvement in change of ejection fraction determined with CMR between 7--15 days and 2--3 months. Further studies are required to establish antioxidant protocols as adjuvant therapies during PCA to prevent MRI and improve the clinical outcomes of patients with AMI.
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